M Yanada

Summary

Affiliation: Nagoya University
Country: Japan

Publications

  1. ncbi Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome
    Masamitsu Yanada
    Nagoya University Graduate School of Medicine, Nagoya, Japan
    Eur J Haematol 78:213-9. 2007
  2. ncbi Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice
    Masamitsu Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya, Aichi 466 8550, Japan
    Leuk Lymphoma 47:1747-53. 2006
  3. ncbi Clinical features and outcome of T-lineage acute lymphoblastic leukemia in adults: a low initial white blood cell count, as well as a high count predict decreased survival rates
    Masamitsu Yanada
    Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya, Aichi 466 8550, Japan
    Leuk Res 31:907-14. 2007
  4. ncbi Disseminated intravascular coagulation in acute leukemia: clinical and laboratory features at presentation
    Masamitsu Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
    Eur J Haematol 77:282-7. 2006
  5. ncbi Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis
    Masamitsu Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Cancer 106:2657-63. 2006
  6. ncbi High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group
    Masamitsu Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
    J Clin Oncol 24:460-6. 2006
  7. ncbi Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease
    M Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
    Bone Marrow Transplant 36:867-72. 2005
  8. ncbi Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis
    M Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Leukemia 19:1345-9. 2005
  9. ncbi Long-term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: a single-center experience
    Masamitsu Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Eur J Haematol 74:418-23. 2005
  10. ncbi Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation
    M Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Bone Marrow Transplant 32:801-7. 2003

Detail Information

Publications34

  1. ncbi Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome
    Masamitsu Yanada
    Nagoya University Graduate School of Medicine, Nagoya, Japan
    Eur J Haematol 78:213-9. 2007
    ..Even after the introduction of all-trans retinoic acid (ATRA), early hemorrhagic death remains a major cause of remission induction failure for acute promyelocytic leukemia (APL)...
  2. ncbi Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice
    Masamitsu Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya, Aichi 466 8550, Japan
    Leuk Lymphoma 47:1747-53. 2006
    ..Future clinical studies need to focus on how imatinib can be incorporated into chemotherapy more effectively by determining the optimal dosage of imatinib, the optimal combinational schedule, and the role of allogeneic HSCT...
  3. ncbi Clinical features and outcome of T-lineage acute lymphoblastic leukemia in adults: a low initial white blood cell count, as well as a high count predict decreased survival rates
    Masamitsu Yanada
    Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya, Aichi 466 8550, Japan
    Leuk Res 31:907-14. 2007
    ..0055 and 0.0037, respectively). Although our findings need confirmation, these results will be helpful in the identification of prognostically distinct subgroups within adult T-ALL...
  4. ncbi Disseminated intravascular coagulation in acute leukemia: clinical and laboratory features at presentation
    Masamitsu Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
    Eur J Haematol 77:282-7. 2006
    ..Although there are two major scoring systems for the clinical diagnosis of disseminated intravascular coagulation (DIC), the validity of these systems for leukemia-associated DIC remains to be confirmed...
  5. ncbi Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis
    Masamitsu Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Cancer 106:2657-63. 2006
    ..Therefore, optimal postremission therapy is a matter of vital concern. In particular, the clinical efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) should be clarified...
  6. ncbi High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group
    Masamitsu Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
    J Clin Oncol 24:460-6. 2006
    ..A novel therapeutic approach is urgently needed for BCR-ABL-positive acute lymphoblastic leukemia (ALL). In this study, we assessed the efficacy and feasibility of chemotherapy combined with imatinib...
  7. ncbi Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease
    M Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
    Bone Marrow Transplant 36:867-72. 2005
    ..Thus, patients who developed extensive chronic GVHD had better survivals (P = 0.0217), and those who developed grade III-IV acute GVHD had worse survivals (P = 0.0023) than did the others...
  8. ncbi Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis
    M Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Leukemia 19:1345-9. 2005
    ..Although it should be borne in mind that this meta-analysis was based on data abstracted from observational studies, these results may justify the risk-adapted therapeutic strategies for AML according to the FLT3 status...
  9. ncbi Long-term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: a single-center experience
    Masamitsu Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Eur J Haematol 74:418-23. 2005
    ..Our findings suggest that the WHO classification may be strengthened by greater emphasis on genetic/cytogenetic information...
  10. ncbi Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation
    M Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Bone Marrow Transplant 32:801-7. 2003
    ..Optimal pre-emptive strategy needs to be determined...
  11. ncbi Allogeneic myeloablative transplantation for patients aged 50 years and over
    M Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Bone Marrow Transplant 34:29-35. 2004
    ..0303, respectively). These findings indicate that allogeneic c-HSCT should be offered to patients over 50 years only if the increased risk of TRM is acceptable, and that a non-TBI regimen is preferable when the transplant is performed...
  12. ncbi Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Jap
    M Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Bone Marrow Transplant 34:331-7. 2004
    ..62, 95% CI: 1.23-2.14, P=0.0007 for OS). This superiority of FK506 was not observed in SIB-HSCT cases. These findings indicate that the use of FK506 instead of CSP for GVHD prophylaxis is beneficial for patients undergoing UD-HSCT...
  13. ncbi Multiplex real-time RT-PCR for prospective evaluation of WT1 and fusion gene transcripts in newly diagnosed de novo acute myeloid leukemia
    Masamitsu Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Leuk Lymphoma 45:1803-8. 2004
    ....
  14. ncbi Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis
    Masamitsu Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Cancer 103:1652-8. 2005
    ..Because the karyotype identified at diagnosis is the most relevant prognostic factor for AML, it should be possible to assess the efficacy more accurately on the basis of cytogenetic risk...
  15. doi Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy
    Masamitsu Yanada
    Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Br J Haematol 143:503-10. 2008
    ....
  16. ncbi Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia
    Masayuki Towatari
    Nagoya University Graduate School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya, Aichi 466 8550, Japan
    Blood 104:3507-12. 2004
    ..This is especially useful because it provides the patients with a better chance to receive an allogeneic HSC transplant...
  17. doi Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy
    Y Inamoto
    Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya 466 8560, Japan
    Bone Marrow Transplant 44:43-9. 2009
    ..Avoiding intensified immunosuppression that damages vascular endothelium until the resolution of i-TAM may improve transplant outcome...
  18. doi Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy
    Masamitsu Yanada
    Nagoya University Graduate School of Medicine, Nagoya, Japan
    Haematologica 93:287-90. 2008
    ..027), and increase the risk of treatment failure by 2.8-fold...
  19. doi Effect of related donor availability on outcome of AML in the context of related and unrelated hematopoietic cell transplantation
    M Yanada
    Department of Hematology, Fujita Health University School of Medicine, Aichi, Japan
    Bone Marrow Transplant 48:390-5. 2013
    ..The extensive use of unrelated HCT for such patients may minimize the potential disadvantage of lacking a related donor...
  20. ncbi Clinical significance of FLT3 in leukemia
    Hitoshi Kiyoi
    Department of Infectious Diseases, Nagoya University Graduate School of Medicine, Japan
    Int J Hematol 82:85-92. 2005
    ..Routine screening of FLT3 mutations is recommended to stratify the patients into distinct risk groups, while the optimal treatment strategy for patients with FLT3 mutations should be further evaluated...
  21. doi Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan
    Hiroto Narimatsu
    Department of Hematology and Oncology, Toyohashi Municipal Hospital, Toyohashi, Japan
    Int J Hematol 88:154-8. 2008
    ..Although these findings need to be confirmed with a larger number of patients, our data indicate that the MRD level at a given time during the early course in CR does not predict the outcome in Japanese patients...
  22. ncbi High incidence of secondary failure of platelet recovery after autologous and syngeneic peripheral blood stem cell transplantation in acute promyelocytic leukemia
    H Narimatsu
    Department of Hematology and Oncology, JA Aichi Showa Hospital, Konan, Japan
    Bone Marrow Transplant 40:773-8. 2007
    ..The unexpectedly high prevalence and the characteristics of SFPR may provide additional information on management following autologous SCT for acute myeloid leukemia...
  23. doi Hematopoietic stem cell transplantation for acute promyelocytic leukemia in second or third complete remission: a retrospective analysis in the Nagoya Blood and Marrow Transplantation Group
    Akio Kohno
    Division of Hematology and Oncology, JA Aichi Showa Hospital, 46 Nobaku, Nobaku cho, Konan, Aichi, Japan
    Int J Hematol 87:210-6. 2008
    ..These data suggest that auto HSCT is very effective for APL in CR2 or CR3, and may be preferable to allo HSCT for a portion of patients. Prospective studies are required to define the role of auto HSCT in the treatment of relapsed APL...
  24. ncbi Syndecan-4 deficiency leads to high mortality of lipopolysaccharide-injected mice
    K Ishiguro
    Department of Biochemistry, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
    J Biol Chem 276:47483-8. 2001
    ..These results indicate that syndecan-4 could be involved in prevention of endotoxin shock, at least partly through the inhibitory action of transforming growth factor-beta1 on IL-1beta production...
  25. doi Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia
    Masamitsu Yanada
    Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa Ku, Nagoya, 466 8550, Japan
    Int J Hematol 89:3-13. 2009
    ..Further improvement in treatment results will be achieved by identifying each patient's disease profile based on information obtained before and during treatment and by optimizing subsequent treatment accordingly...
  26. ncbi [Treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia]
    Masamitsu Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine
    Nihon Rinsho 65:479-82. 2007
  27. ncbi Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia
    Masamitsu Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine
    Intern Med 45:259-64. 2006
    ..Empirical antifungal therapy with amphotericin B has been the standard of care for these patients; however, there remains a need for less toxic alternative drugs...
  28. ncbi Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission
    Masamitsu Yanada
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2756-60. 2007
    ..Potential cure of acute myeloid leukemia (AML) is now a widely accepted idea, but it is uncertain whether there is heterogeneity in the failure rate in patients once they have been in complete remission (CR) for various periods of time...
  29. ncbi Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia
    Masamitsu Yanada
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States
    Leuk Res 32:1505-9. 2008
    ..38, p=0.02), as was higher platelet count (hazard ratio 1.35, p=0.04). These findings suggest that blood counts at CR, information readily available, are useful in prognostication in AML...
  30. ncbi Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy
    Hitoshi Zembutsu
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108 8639, Japan
    Int J Oncol 31:313-22. 2007
    ..Our results suggest that achievement of continuous response with imatinib-combined chemotherapy can be predicted by expression patterns in this set of genes, leading to achievement of 'personalized therapy' for treatment of this disease...
  31. ncbi Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome
    Masamitsu Yanada
    Br J Haematol 138:555-7. 2007
  32. doi Relapse and death during first remission in acute myeloid leukemia
    Masamitsu Yanada
    Haematologica 93:633-4. 2008
  33. doi Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia
    Masamitsu Yanada
    Haematologica 93:1263-5. 2008
  34. ncbi Randomized controlled trials of treatments for hematologic malignancies: study characteristics and outcomes
    Masamitsu Yanada
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:334-9. 2007
    ..Therefore, the intention in the current study was to clarify the differential elements of studies with 'positive' and 'negative' outcomes...